| 2017 |
A missense mutation in ANGPT1 (p.A119S) reduces the formation of multimeric forms of the protein and impairs its ability to bind its natural receptor TIE2 (tunica interna endothelial cell kinase 2), establishing a mechanistic link between ANGPT1 multimerization/receptor binding and maintenance of vascular integrity (hereditary angioedema). |
Protein analysis of patient plasma, recombinant mutant protein expression, receptor binding assay |
The Journal of allergy and clinical immunology |
Medium |
28601681
|
| 2015 |
The histone H3K9 demethylase KDM3B transcriptionally represses ANGPT1 independently of its JmjC-domain demethylase activity, acting via interaction with the co-repressor SMRT to form a repressor complex at the ANGPT1 promoter; KDM3B depletion increases cell proliferation and motility. |
Reporter assay, co-immunoprecipitation (KDM3B–SMRT interaction), chromatin immunoprecipitation at ANGPT1 promoter, MTT and wound-healing assays with KDM3B knockdown |
BMB reports |
Medium |
25413303
|
| 2012 |
Enhanced Angpt1/Tie2 signaling in osteoblasts (via COMP-Angpt1 transgenic overexpression) affects hematopoietic lineage differentiation during early development and increases the long-term bone marrow reconstitution ability of LSK (Lin−Sca-1+c-Kit+) hematopoietic stem cells. |
Conditional transgenic mouse model (Col1a1-Cre × COMP-Angpt1), peripheral blood analysis, bone marrow transplantation/reconstitution assay |
Biochemical and biophysical research communications |
Medium |
23149415
|
| 2016 |
Inhibition of ANGPT1 in follicular fluid from OHSS patients (using a neutralizing antibody) restores vascular branch points, integrin αvβ3 levels, claudin-5, VE-cadherin, and phosphorylated β-catenin, and partially reverses actin redistribution in endothelial cells, demonstrating that ANGPT1 modulates tight and adherens junction proteins to regulate vascular permeability. |
ANGPT1-neutralizing antibody in chorioallantoic membrane (CAM) assay and endothelial cell culture; immunofluorescence of junction proteins and cytoskeletal markers |
Reproduction, fertility, and development |
Medium |
25485810
|
| 2024 |
In zebrafish, Angpt1 binds specifically to Tie1 (not other Tie receptors) as a ligand, activates Tie1 signaling (monitored by nuclear exclusion of EGFP-Foxo1a in sprouting endothelial cells), promotes endothelial cell migration and proliferation, and drives lymphatic specification during early lymphangiogenesis, at least in part by modulating Vegfc/Vegfr3 signaling. |
Comprehensive zebrafish mutant analysis (angpt1, tie1, other angiopoietin/Tie receptor mutants), ligand-binding assay, live EGFP-Foxo1a nuclear-import reporter, genetic epistasis with Vegfc/Vegfr3 |
Development (Cambridge, England) |
High |
38742432
|
| 2025 |
In RUNX1-MECOM-expressing leukemia cells, Angpt1 and its receptor Tek (Tie2) are co-expressed and form an autocrine signaling loop: exogenous Angpt1 stimulation phosphorylates endogenous Tek, which activates downstream Akt. HDAC inhibitors (TSA and VPA) downregulate both Tek and Angpt1 expression, disrupting this loop and inhibiting leukemia cell growth via cell-cycle arrest and apoptosis. |
Quantitative RT-PCR array, Western blot for Angpt1/Tek protein co-expression, Angpt1 stimulation with phospho-Tek and phospho-Akt detection, HDAC inhibitor treatment, in vitro proliferation and in vivo transplantation assay |
Leukemia research |
Medium |
40570741
|
| 2025 |
Sympathetic innervation stimulates β-adrenergic receptors on perivascular cells to drive Angpt1 production; perivascular-derived Angpt1 maintains the quiescent state of post-natal skeletal muscle stem cells. Sympathetic denervation reduces perivascular Angpt1, leading to vascular remodeling, depletion of the muscle stem cell pool, and impaired tissue repair. |
Sympathetic denervation model, pharmacologic and genetic β-adrenergic receptor modulation, immunofluorescence/live imaging of muscle stem cell niche, loss-of-function for Angpt1 |
Developmental cell |
Medium |
40752496
|
| 2024 |
In pericytes, CCL28 reprograms retinoic acid (RA) metabolism and increases ANGPT1 expression via RXRα transcriptional activation of the ANGPT1 promoter (validated by ChIP-qPCR), thereby enhancing endothelial cell stability and promoting tumor vascular normalization after anti-angiogenesis therapy. |
CCL28 overexpression/knockout in vivo models, RNA sequencing of pericytes, ChIP-qPCR for RXRα binding to ANGPT1 promoter, LC-MS metabolomics, Western blot |
Journal of experimental & clinical cancer research |
Medium |
39075504
|
| 2025 |
Angpt1 carried by pericyte-derived extracellular vesicles (PCEVs) activates the PI3K/Akt pathway in endothelial cells; knockdown of Angpt1 in PCEVs suppresses PI3K/Akt activation and abolishes the protective effects on intestinal vascular barrier function and pericyte recruitment in sepsis. |
Proteomic analysis of PCEVs, Angpt1 knockdown in PCEVs, CLP sepsis rat model, in vitro endothelial assays, Western blot for phospho-PI3K and phospho-Akt |
Stem cell research & therapy |
Medium |
39940043
|
| 2025 |
HMGB2 ablation in NK cells induces ANGPT1 expression, which activates the PI3K/AKT pathway; ANGPT1 knockdown in HMGB2-KO NK cells reduces PI3K/AKT activation and diminishes enhanced NK cytotoxicity (granzyme B, perforin, IFN-γ, TNF-α release and tumor lysis), establishing an ANGPT1/PI3K/AKT axis downstream of HMGB2 in NK cell function. |
CRISPR/Cas9 KO and RNA interference of HMGB2, ANGPT1 knockdown in KO-HMGB2 cells, flow cytometry for cytotoxic markers, tumor lysis assay |
Frontiers in immunology |
Medium |
41280896
|